At a glance
ClinicalIndex Comparison RecordN/ACompleted· 847 enrolled
Drug / intervention
Not specified
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Treatment Patterns And Clinical Outcomes Among Patients in Latin America Receiving First Line Palbociclib Combinations For HORMONE RECEPTOR POSITIVE/ HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 NEGATIVE (HR+/HER2-) Advanced/Metastatic Breast Cancer In Real World Settings
In Brief
An observational study for Breast Cancer Metastatic. Completed, enrolled 847 participants across 2 sites in 2 countries.
Detailed Summary
To describe patient demographics, clinical characteristics, treatment patterns and clinical outcomes of adult female patients who have received palbociclib combination treatments as first line therapy, regardless of combination partner and labelled use in real world settings across Latin America.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsBreast Cancer Metastatic
CountriesArgentina, United Kingdom
Collaborators--
Timeline
N/ACompletedFinished
2020202120222023202420252026
Enrollment StartMay 2019
Primary CompletionMar 2021
First PostedDec 2021
TodayJul 2026
First PostedDec 13, 2021
Enrollment StartMay 15, 2019
Primary CompletionMar 12, 2021
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 4.6 years ago